Improving the development of cancer biomarkers using advanced statistical methods
Official title: Accelerating biomarker development through novel statistical methods for analyzing phase III/IV studies
Funded at Fred Hutchinson Cancer Center · NIH-10993177 · Data updated 2026-11-12
This study is working on new ways to improve cancer tests and treatments, so patients can get more accurate and quicker results, helping them find and fight cancer better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | December 1, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $401,719 |
| NIH project number | 5R01CA277133-03 |
| Project ID | NIH-10993177 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals undergoing cancer screening or treatment who may benefit from improved biomarker development.
✕Less likely to help
Patients with cancers that are not being studied or those who are not eligible for current biomarker trials may not receive benefits from this research.
What this research studies
This research focuses on enhancing the development and validation of cancer biomarkers, which are crucial for precision medicine. By creating innovative statistical tools, the project aims to streamline the analysis of phase III and IV studies, making it easier to assess the effectiveness of cancer screening and treatment. The methods will help combine data from different studies and improve the design of clinical trials, ultimately leading to faster and more reliable biomarker validation. Patients may benefit from more accurate and timely cancer detection and treatment options as a result of this work.
Why it matters
Potential benefit: If successful, this research could lead to quicker and more effective cancer detection and treatment options for patients.
How similar studies have gone: Other research has shown success in using advanced statistical methods to improve biomarker validation, indicating that this approach has potential for significant impact.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Huang, Ying — Fred Hutchinson Cancer Center
- Study coordinator: Huang, Ying
Related research
Other NIH-funded projects on the same topics.
-
How brain glia prune neuron fragments in a worm model
Researchers study how brain support cells called glia remove pieces of living neurons in a tiny worm to learn about brain aging and diseases like Alzheimer's.
-
Understanding and Targeting Lineage Plasticity in Prostate Cancer with Genomic-Based Neoadjuvant Therapy
A broad research program at Fred Hutchinson Cancer Center is exploring how aggressive prostate cancers change their cell states in response to therapy and how to block these changes.
-
Personalized cancer drug testing on patient tumor cells
Aiming to test many FDA-approved cancer drugs on a patient’s own tumor cells to identify effective options when standard therapies fail.
-
MOSAAIC: Using health records to track heart disease in Asian American Communities
A big, dedicated effort is testing whether electronic health records can more quickly and accurately track heart and blood vessel problems in Asian American populations.
-
Targeting gut microbes to prevent progression to multiple myeloma
Researchers are testing how specific gut bacteria might trigger immune changes linked to early blood cancer stages and whether targeting these microbes could help prevent progression to multiple myeloma.
-
eDyNAmiC: Understanding extrachromosomal DNA in cancer and how it drives aggressiveness
A cancer research project at Fred Hutchinson Cancer Center is studying abnormal circular DNA pieces (ecDNA) that help cancers grow and resist treatment, with the aim of finding ways to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.